ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA

Figure 3 Effects of esophageal cancer-related gene 2 combined with cisplatin (DDP) on cell viability in EC9706/DDP cells. Cells were treated with dimethyl sulfoxide, ECRG2 (6.5 μg/mL) alone, DDP (3 μg/mL) alone, or a combination of ECRG2 (6.5 μg/mL) and DDP (3 μg/mL) for 24 h, 48 h, 72 h, and 96 h. Cell viability was detected via MTT assay.